IDH1 and acute myeloid leukemia: Ivosidenib (AG-120), an IDH1 inhibitor, and enasidenib (AG-221), an IDH2 inhibitor, are FDA approved in the U.S. for refractory AML withmIDH1 andmIDH2, respectively.